In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.